포스콜린

Hepatic cytochrome P450 mediates interaction between warfarin and Coleus forskohlii extract in vivo and in vitro.

1. J Pharm Pharmacol. 2012 Dec;64(12):1793-801. doi: 10.1111/j.2042-7158.2012.01563.x. Epub 2012 Jul 19. Hepatic cytochrome P450 mediates interaction between warfarin and Coleus forskohlii extract in vivo and in vitro. Yokotani K(1), Chiba T, Sato Y, Taki Y, Yamada S, Shinozuka K, Murata M, Umeg

Forskolin: upcoming antiglaucoma molecule.

2. J Postgrad Med. 2012 Jul-Sep;58(3):199-202. doi: 10.4103/0022-3859.101396. Forskolin: upcoming antiglaucoma molecule. Wagh VD(1), Patil PN, Surana SJ, Wagh KV. Author information: (1)Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Near Karwand Naka

Forskolin and derivatives as tools for studying the role of cAMP.

3. Pharmazie. 2012 Jan;67(1):5-13. Forskolin and derivatives as tools for studying the role of cAMP. Alasbahi RH(1), Melzig MF. Author information: (1)Institute of Pharmacy, Freie Universität Berlin, Germany. Forskolin (7beta-acetoxy-1alpha,6beta,9alpha-trihydroxy-8,13-epoxy-labd-14-en-11-one)

Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep.

4. Thromb Haemost. 1989 Feb 28;61(1):106-10. Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep. Agarwal KC(1), Zielinski BA, Maitra RS. Author information: (1)Section of Biochemical Pharmacology, Brown University, Providence, RI

Forskolin lowers intraocular pressure by reducing aqueous inflow.

5. Invest Ophthalmol Vis Sci. 1984 Mar;25(3):268-77. Forskolin lowers intraocular pressure by reducing aqueous inflow. Caprioli J, Sears M, Bausher L, Gregory D, Mead A. Forskolin is a diterpene derivative of the plant Coleus forskohlii that stimulates adenylate cyclase activity without interact

Novel Multi-Ingredient Supplement Facilitates Weight Loss and Improves Body Composition in Overweight and Obese Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

1. Nutrients. 2023 Aug 23;15(17):3693. doi: 10.3390/nu15173693. Novel Multi-Ingredient Supplement Facilitates Weight Loss and Improves Body Composition in Overweight and Obese Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nederveen JP(1), Mastrolonardo AJ(1), Xhuti D(1), Di Carlo A(1), Manta K(1), Fuda MR(1), Tarnopolsky MA(1)(2). Author information: (1)Department of Pediatrics, Faculty of Health Sciences, McMaster University Medical Center (MUMC), Hamilton, ON L8N 3Z5, Canada. (2)Exerkine Corporation, McMaster University Medical Center (MUMC), Hamilton, ON L8N 3Z5, Canada. BACKGROUND: Despite the growing recognition of the obesity crisis, its rates continue to rise. The current first-line therapies, such as dietary changes, energy restriction, and physical activity, are typically met with poor adherence. Novel nutritional interventions can address the root causes of obesity, including mitochondrial dysfunction, and facilitate weight loss. OBJECTIVE: The objective of this study was to investigate the effects of a multi-ingredient nutritional supplement designed to facilitate mitochondrial function and metabolic health outcomes over a 12 wk period. METHODS: Fifty-five overweight and/or obese participants (age (mean ± SEM): 26 ± 1; body mass index (BMI) (kg/m2): 30.5 ± 0.6) completed this double-blind, placebo-controlled clinical trial. Participants were randomized to 12 wks of daily consumption of multi-ingredient supplement (MIS; n = 28; containing 50 mg forskolin, 500 mg green coffee bean extract, 500 mg green tea extract, 500 mg beet root extract, 400 mg α-lipoic acid, 200 IU vitamin E, and 200 mg CoQ10) or control placebo (PLA, n = 27; containing microcrystalline cellulose) matched in appearance. The co-primary outcomes were bodyweight and fat mass (kg) changes. The secondary outcomes included other body composition measures, plasma markers of obesity, fatty liver disease biomarkers, resting energy metabolism, blood pressure, physical performance, and quality of life. The post-intervention differences between MIS and PLA were examined via ANCOVA which was adjusted for the respective pre-intervention variables. RESULTS: After adjustment for pre-intervention data, there was a significant difference in weight (p < 0.001) and fat mass (p < 0.001) post-intervention between the PLA and MIS treatment arms. Post-intervention weight and fat mass were significantly lower in MIS. Significant post-intervention differences corrected for baseline were found in markers of clinical biochemistry (AST, p = 0.017; ALT, p = 0.008), molecular metabolism (GDF15, p = 0.028), and extracellular vesicle-associated miRNA species miR-122 and miR-34a in MIS (p < 0.05). CONCLUSIONS: Following the 12 wks of MIS supplementation, weight and body composition significantly improved, concomitant with improvements in molecular markers of liver health and metabolism. DOI: 10.3390/nu15173693 PMCID: PMC10490028 PMID: 37686725 [Indexed for MEDLINE] Conflict of interest statement: Exerkine Corporation is a biotechnology company that develops and commercializes therapies based on supplements, exercise-derived factors (&lsquo;exerkines&rsquo;), and extracellular vesicles to treat genetic disorders, chronic diseases, and aging. MAT is the founder, CEO, and CSO of Exerkine Corporation. At the time of publication submission, a Canadian patent (CA 3050823) was granted for the supplement described herein. The author warrants that the COI did not impact the execution of the research, including data collection, analyses, and interpretation, or in the decision to publish the manuscript.

Nutritional supplementation in the treatment of glaucoma: A systematic review.

2. Surv Ophthalmol. 2019 Mar-Apr;64(2):195-216. doi: 10.1016/j.survophthal.2018.09.005. Epub 2018 Oct 6. Nutritional supplementation in the treatment of glaucoma: A systematic review. Loskutova E(1), O'Brien C(2), Loskutov I(3), Loughman J(4). Author information: (1)Centre for Eye Research Ireland, Dublin Institute of Technology, Grangegorman Lower, Dublin, Ireland. Electronic address: losk.katerina@gmail.com. (2)Centre for Eye Research Ireland, Dublin Institute of Technology, Grangegorman Lower, Dublin, Ireland; Institute of Ophthalmology, Mater Misericordiae University Hospital, Dublin, Ireland. (3)Clinical Research centre, Central Hospital RZD, Moscow, Russia. (4)Centre for Eye Research Ireland, Dublin Institute of Technology, Grangegorman Lower, Dublin, Ireland; African Vision Research Institute, University of KwaZulu Natal, Durban, South Africa. Current treatment strategies for glaucoma are limited to halting disease progression and do not restore lost visual function. Intraocular pressure is the main risk factor for glaucoma, and intraocular pressure-lowering treatment remains the mainstay of glaucoma treatment, but even successful intraocular pressure reduction does not stop the progression of glaucoma in all patients. We review the literature to determine whether nutritional interventions intended to prevent or delay the progression of glaucoma could prove to be a valuable addition to the mainstay of glaucoma therapy. A total of 33 intervention trials were included in this review, including 21 randomized controlled trials. These suggest that flavonoids exert a beneficial effect in glaucoma, particularly in terms of improving ocular blood flow and potentially slowing progression of visual field loss. In addition, supplements containing forskolin have consistently demonstrated the capacity to reduce intraocular pressure beyond the levels achieved with traditional therapy alone; however, despite the strong theoretical rationale and initial clinical evidence for the beneficial effect of dietary supplementation as an adjunct therapy for glaucoma, the evidence is not conclusive. More and better quality research is required to evaluate the role of nutritional supplementation in glaucoma. Copyright © 2018 Elsevier Inc. All rights reserved. DOI: 10.1016/j.survophthal.2018.09.005 PMID: 30296451 [Indexed for MEDLINE]

Oral Administration of Forskolin, Homotaurine, Carnosine, and Folic Acid in Patients with Primary Open Angle Glaucoma: Changes in Intraocular Pressure, Pattern Electroretinogram Amplitude, and Foveal Sensitivity.

3. J Ocul Pharmacol Ther. 2016 Apr;32(3):178-83. doi: 10.1089/jop.2015.0121. Epub 2016 Jan 15. Oral Administration of Forskolin, Homotaurine, Carnosine, and Folic Acid in Patients with Primary Open Angle Glaucoma: Changes in Intraocular Pressure, Pattern Electroretinogram Amplitude, and Foveal Sensitivity. Mutolo MG(1), Albanese G(2), Rusciano D(3), Pescosolido N(2). Author information: (1)1 Faculty of Medicine and Dentistry, Azienda Ospedaliera Sant'Andrea, Rome University La Sapienza , Rome, Italy . (2)2 Faculty of Medicine and Dentistry, Policlinic Umberto I, Rome University La Sapienza , Rome, Italy . (3)3 Sooft Italia SpA , Rome, Italy . PURPOSE: To evaluate the effects of a food supplement containing forskolin, homotaurine, carnosine, folic acid, vitamins B1, B2, B6, and magnesium in patients with primary open angle glaucoma (POAG) already in treatment and compensated by intraocular pressure (IOP)-lowering drugs, during a period of 12 months. METHODS: Twenty-two patients (44 eyes) with POAG, with their IOP compensated by topical drugs, were enrolled and randomly assigned to the food supplement or control treatment group. The additional food supplement treatment consisted of 2 tablets per day (1 in the morning, 1 in the evening) given for 1 year of a balanced association of homotaurine, Coleus forskohlii root extract, L-carnosine, folic acid, vitamins B1, B2, B6, and magnesium. Pattern Electroretinogram (PERG) amplitude, foveal sensitivity obtained with the visual field analyzer frequency doubling technology, and IOP were detected at enrollment (T0), 3 months (T1), 6 months (T2), 9 months (T3), and 12 months (T4). RESULTS: We observed in treated patients a significant further decrease of IOP and an improvement of PERG amplitude at 6, 9, and 12 months, and foveal sensitivity at 12 months. All values remained substantially stable in control patients. CONCLUSIONS: The results of the present pilot study indicate that the components of the food supplement reach the eye in a detectable manner, as evidenced by the effects on the IOP. Moreover, they suggest a short-term neuroactive effect, as indicated by the improvement of PERG amplitude and foveal sensitivity in treated, but not in control patients. DOI: 10.1089/jop.2015.0121 PMID: 26771282 [Indexed for MEDLINE]

Rooibos influences glucocorticoid levels and steroid ratios in vivo and in vitro: a natural approach in the management of stress and metabolic disorders?

4. Mol Nutr Food Res. 2014 Mar;58(3):537-49. doi: 10.1002/mnfr.201300463. Epub 2013 Sep 11. Rooibos influences glucocorticoid levels and steroid ratios in vivo and in vitro: a natural approach in the management of stress and metabolic disorders? Schloms L(1), Smith C, Storbeck KH, Marnewick JL, Swart P, Swart AC. Author information: (1)Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa. SCOPE: To determine the effect of Rooibos (Aspalathus linearis) on glucocorticoid biosynthesis and inactivation in vivo and in vitro. METHODS AND RESULTS: Ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) analyses of in vivo studies showed that human Rooibos consumption increased cortisone plasma levels in males (p = 0.0465) and reduced cortisol:cortisone ratios in males and females (p = 0.0486) at risk for cardiovascular disease. In rats, corticosterone (CORT) (p = 0.0275) and deoxycorticosterone (p = 0.0298) levels as well as the CORT:testosterone ratio (p = 0.0009) decreased following Rooibos consumption. The inactivation of cortisol was investigated in vitro by expressing 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and type 2 (11βHSD2) in CHO-K1 cells. Rooibos inhibited 11βHSD1, which resulted in a significant reduction in the cortisol:cortisone ratio (p < 0.01). No significant effect was detected on 11βHSD2. In vitro studies in adrenal H295R cells showed that Rooibos and rutin, one of the more stable flavonoid compounds present in Rooibos, significantly reduced the levels of cortisol and CORT in cells stimulated with forskolin to mimic a stress response. CONCLUSION: In vivo studies demonstrate that Rooibos significantly decreased glucocorticoid levels in rats and steroid metabolite ratios linked to metabolic disorders--cortisol:cortisone in humans and CORT:testosterone in rats. Results obtained at cellular level elucidate possible mechanisms by which these effects were achieved. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. DOI: 10.1002/mnfr.201300463 PMID: 24022885 [Indexed for MEDLINE]

Treatment of glaucomatous patients by means of food supplement to reduce the ocular discomfort: a double blind randomized trial.

5. Eur Rev Med Pharmacol Sci. 2013 Apr;17(8):1117-22. Treatment of glaucomatous patients by means of food supplement to reduce the ocular discomfort: a double blind randomized trial. Nebbioso M(1), Rusciano D, Pucci B, Zicari AM, Grenga R, Pescocolido N. Author information: (1)Department of Sense Organs, Sapienza University of Rome, Rome, Italy. marcella.nebbioso@uniroma1.it BACKGROUND AND AIM: Chronic use of multi-dose eye drops containing preservatives, such as it may happen in patients affected by primary open angle glaucoma, often results in a damage of the ocular surface due to the inherent toxicity of preservatives, that with time may lead to a lacrimal dysfunction syndrome and eye dryness. PATIENTS AND METHODS: This double blind, randomized, pilot study was conducted on 38 glaucomatous patients suffering from dry eye induced by long-term use of eye drops preserved with BAK. RESULTS: Treatment of these patients with a food supplement containing an association of forskolin, rutin and vitamins B1 and B2 for 30 days increased significantly their OPI values and improved the symptoms of dry eye with respect to a placebo-treated control group. CONCLUSIONS: The association of forskolin, rutin and vitamins B1 and B2 appears to be protective for the ocular surface, contributing to restore a normal equilibrium of the tear film in those subjects in which toxic agents such as BAK had determined alterations of its homeostasis. PMID: 23661528 [Indexed for MEDLINE]

Oral administration of forskolin and rutin contributes to intraocular pressure control in primary open angle glaucoma patients under maximum tolerated medical therapy.

6. J Ocul Pharmacol Ther. 2012 Oct;28(5):536-41. doi: 10.1089/jop.2012.0021. Epub 2012 Jun 25. Oral administration of forskolin and rutin contributes to intraocular pressure control in primary open angle glaucoma patients under maximum tolerated medical therapy. Vetrugno M(1), Uva MG, Russo V, Iester M, Ciancaglini M, Brusini P, Centofanti M, Rossetti LM. Author information: (1)Ophthalmology Department, University of Bari, Bari, Italy. michelevetrugno@libero.it BACKGROUND: Tight control of intraocular pressure (IOP) is still the only therapeutic approach available for the treatment of primary open angle glaucoma (POAG). However, some patients do not respond adequately to hypotonising drugs, and despite multiple drug combinations they cannot reach their target IOP. Forskolin is a natural compound that has already shown efficacy in IOP reduction following topical application. PURPOSE: The aim of this study was to evaluate the effects on the IOP of a food supplement containing forskolin and rutin when administered to POAG patients under maximum tolerated medical therapy (MTMT) and on a waiting list for filtrating surgery to further decrease their IOP. METHODS: The design of the study was open and case-controlled. Ninety-seven (52 in the treatment group, and 45 in the reference group) patients were enrolled in 8 different glaucoma centers in Italy, all under MTMT and with IOP enrollment values above their target pressure. During the 30 days before surgery, patients in the treatment group were prescribed 2 tablets per day of a food supplement containing rutin and forskolin in addition to their usual topical drug treatment. Their IOP values were measured at 3 time points during the day, at enrollment and once a week until surgery. Control patients continued only with their normal topical therapy. RESULTS: All patients in the treatment group, independently of the combination drug therapy that they were taking, showed a further 10% decrease (P<0.01) of their IOP, starting from 1 week after introduction of the oral supplement and lasting until the last evaluation before surgery. This decrease was more evident (15% of the enrollment value; P<0.01) in those subjects with high (IOP≥21 mmHg) enrollment values rather than in those with low (IOP<21) enrollment values (9%; P<0.01). On the contrary, IOP values in the control group remained stable from the beginning to the end of the observation period, independently of their enrollment values. CONCLUSIONS: Forskolin and rutin given as oral treatment appear to contribute to a better control and a further small reduction of IOP in patients who were poorly responsive to multitherapy treatment. DOI: 10.1089/jop.2012.0021 PMID: 22731245 [Indexed for MEDLINE]

Efficacy of forskolin as a promising therapy for chronic olfactory dysfunction post COVID-19.

7. Eur Arch Otorhinolaryngol. 2024 Nov;281(11):5793-5799. doi: 10.1007/s00405-024-08802-x. Epub 2024 Jul 13. Efficacy of forskolin as a promising therapy for chronic olfactory dysfunction post COVID-19. Abdelazim MH(1), Alsenani F(2), Alnuhait M(3), Alshammari AS(3), Altemani AH(4), Althagafi EA(5), Waggas DS(6), Abdelazim AH(7), Alharbi A(3). Author information: (1)Department of Otolaryngology, Faculty of Medicine, Al-Azhar University, Damietta, Egypt. (2)Department of Pharmaceutical Sciences, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. (3)Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. (4)Department of Family and Community Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia. (5)Department of pharmaceutical care, King Fahad General Hospital, Jeddah, Saudi Arabia. (6)Department of Pathological Sciences, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia. (7)Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. ahmed.hussienabdelazim@hotmail.com. PURPOSE: Olfactory dysfunction is increasingly common among COVID-19 patients, impacting their well-being. Reports have demonstrated decreased levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate among patients with chronic olfactory dysfunction. A prospective randomized clinical trial was developed to demonstrate the efficacy of an oral forskolin regimen treatment, an adenylyl cyclase activator that raises intracellular levels of cyclic adenosine monophosphate, for the treatment of olfactory dysfunction following COVID-19, compared to placebo regimen. METHODS: The study enrolled 285 participants with persistent olfactory dysfunction post COVID-19 infection, randomly assigning them to receive either placebo capsules (n = 120) or oral forskolin capsules (n = 165). Follow-up was conducted to track progress, with 18 participants from the placebo group and 12 from the forskolin group lost during this period. Olfactory function was assessed using the "Sniffin' Sticks" test, measuring threshold, discrimination and identification scores before and after treatment. RESULTS: Subjects administered forskolin capsules demonstrated a significant enhancement in their composite TDI (threshold, discrimination and identification) score, suggesting a notable amelioration in olfactory functionality. Moreover, the discrimination and identification scores notably improved within the forskolin group. Conversely, no significant alterations were observed in the threshold scores. CONCLUSION: This study suggests that forskolin can contribute potentially to improve chronic olfactory dysfunction post COVID-19. TRIAL REGISTRATION: DFM-IRB00012367-23-10-001. © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. DOI: 10.1007/s00405-024-08802-x PMID: 39001919 [Indexed for MEDLINE]

Defatting of donor transplant livers during normothermic perfusion-a randomised clinical trial: study protocol for the DeFat study.

8. Trials. 2024 Jun 17;25(1):386. doi: 10.1186/s13063-024-08189-4. Defatting of donor transplant livers during normothermic perfusion-a randomised clinical trial: study protocol for the DeFat study. Abbas SH(1), Ceresa CDL(2), Hodson L(3), Nasralla D(2), Watson CJE(4), Mergental H(5)(6), Coussios C(7), Kaloyirou F(8), Brusby K(8), Mora A(9), Thomas H(10), Kounali D(11), Keen K(8), Pollok JM(2), Gaurav R(4), Iype S(2), Jassem W(12), Perera MTP(5), Hakeem AR(12)(13), Knight S(#)(14), Friend PJ(#)(14). Author information: (1)Nuffield Department of Surgical Sciences, University of Oxford, The Churchill Hospital, Oxford, OX3 7LJ, UK. hussain.abbas@nds.ox.ac.uk. (2)Royal Free London NHS Foundation Trust, The Royal Free Hospital, Pond St, Hampstead, London, NW3 2QG, UK. (3)Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, The Churchill Hospital, Oxford, OX3 7LJ, UK. (4)Department of Surgery, Addenbrooke's Hospital, Hills Road, University of Cambridge, Box 202, Cambridge, CB2 2QQ, UK. (5)Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, B15 2TH, UK. (6)TransMedics Inc, 200 Minuteman Road, Andover, MA, 01810, USA. (7)Institute of Biomedical Engineering, Old Road Campus Research Building, University of Oxford, Oxford, OX3 7DQ, UK. (8)NHSBT CTU, Long Road, Cambridge, CB2 0PT, UK. (9)Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0BB, UK. (10)NHS Blood and Transplant Clinical Trials Unit, Fox Den Road, Stoke Gifford, Bristol, BS34 8RR, UK. (11)Oxford Clinical Trials Research Unit (OCTRU), Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Medical Sciences Division, The Botnar Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. (12)Kings College Hospital, King's College Hospital NHS Foundation Trust, Denmark Hill, London, SE5 9RS, UK. (13)St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds, LS9 7TF, UK. (14)Nuffield Department of Surgical Sciences, University of Oxford, The Churchill Hospital, Oxford, OX3 7LJ, UK. (#)Contributed equally BACKGROUND: Liver disease is the third leading cause of premature death in the UK. Transplantation is the only successful treatment for end-stage liver disease but is limited by a shortage of suitable donor organs. As a result, up to 20% of patients on liver transplant waiting lists die before receiving a transplant. A third of donated livers are not suitable for transplant, often due to steatosis. Hepatic steatosis, which affects 33% of the UK population, is strongly associated with obesity, an increasing problem in the potential donor pool. We have recently tested defatting interventions during normothermic machine perfusion (NMP) in discarded steatotic human livers that were not transplanted. A combination of therapies including forskolin (NKH477) and L-carnitine to defat liver cells and lipoprotein apheresis filtration were investigated. These interventions resulted in functional improvement during perfusion and reduced the intrahepatocellular triglyceride (IHTG) content. We hypothesise that defatting during NMP will allow more steatotic livers to be transplanted with improved outcomes. METHODS: In the proposed multi-centre clinical trial, we will randomly assign 60 livers from donors with a high-risk of hepatic steatosis to either NMP alone or NMP with defatting interventions. We aim to test the safety and feasibility of the defatting intervention and will explore efficacy by comparing ex-situ and post-reperfusion liver function between the groups. The primary endpoint will be the proportion of livers that achieve predefined functional criteria during perfusion which indicate potential suitability for transplantation. These criteria reflect hepatic metabolism and injury and include lactate clearance, perfusate pH, glucose metabolism, bile composition, vascular flows and transaminase levels. Clinical secondary endpoints will include proportion of livers transplanted in the two arms, graft function; cell-free DNA (cfDNA) at follow-up visits; patient and graft survival; hospital and ITU stay; evidence of ischemia-reperfusion injury (IRI); non-anastomotic biliary strictures and recurrence of steatosis (determined on MRI at 6 months). DISCUSSION: This study explores ex-situ pharmacological optimisation of steatotic donor livers during NMP. If the intervention proves effective, it will allow the safe transplantation of livers that are currently very likely to be discarded, thereby reducing waiting list deaths. TRIAL REGISTRATION: ISRCTN ISRCTN14957538. Registered in October 2022. © 2024. The Author(s). DOI: 10.1186/s13063-024-08189-4 PMCID: PMC11181618 PMID: 38886851 [Indexed for MEDLINE] Conflict of interest statement: Peter Friend and Constantin Coussios are co-founders and shareholders in OrganOx (a University of Oxford spinout company). They receive consultancy payments as non-executive chief medical and chief technical officers, respectively, of the company. Simon Knight, David Nasralla and Carlo Ceresa have received consultancy income from OrganOx for assisting with the design and conduct of previous trials. Hynek Mergental is employed by Transmedics who have no involvement or participation in the DeFat study. Peter Friend, Constantin Coussios and Simon Knight will be not be involved in approaching, consenting, recruiting or in the clinical management of patients in the proposed trial (the Oxford Transplant Centre is not a liver transplant unit).

Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management.

9. Surgery. 2019 Mar;165(3):571-578. doi: 10.1016/j.surg.2018.08.007. Epub 2018 Oct 1. Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management. Jahansouz C(1), Xu H(2), Kizy S(1), Thomas AJ(3), Josephrajan A(2), Hertzel AV(2), Foncea R(2), Connett JC(3), Billington CJ(4), Jensen M(5), Korner J(6), Bernlohr DA(2), Ikramuddin S(7). Author information: (1)Department of Surgery, University of Minnesota, Minneapolis, MN. (2)Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN. (3)Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN. (4)Department of Medicine, Division of Endocrinology & Diabetes, University of Minnesota, Minneapolis, MN. (5)Department of Medicine, Division of Endocrinology & Diabetes, Mayo Clinic, Rochester, MN. (6)Department of Medicine, Division of Endocrinology, Columbia University Medical Center, New York, NY. (7)Department of Surgery, University of Minnesota, Minneapolis, MN. Electronic address: Ikram001@umn.edu. BACKGROUND: Serum concentrations of fatty acid binding protein 4, an adipose tissue fatty acid chaperone, have been correlated with insulin resistance and cardiovascular risk factors. The objective of this study were to assess relationships among Roux-en-Y gastric bypass, intensive lifestyle modification and medical management protocol, fatty acid binding protein 4, and metabolic parameters in obese patients with severe type 2 diabetes mellitus; and to evaluate the relative contribution of abdominal subcutaneous adipose and visceral adipose to the secretion of fatty acid binding protein 4. METHODS: Participants were randomly assigned to intensive lifestyle modification and medical management protocol (n = 29) or to intensive lifestyle modification and medical management protocol augmented with Roux-en-Y gastric bypass (n = 34). Relationships among fatty acid binding protein 4 and demographic characteristics, metabolic parameters, and 12-month changes in these values were examined. Visceral and subcutaneous adipose tissue explants from obese nondiabetic patients (n = 5) were obtained and treated with forskolin to evaluate relative secretion of fatty acid binding protein 4 in the different adipose tissue depots. RESULTS: The intensive lifestyle modification and medical management protocol and Roux-en-Y gastric bypass cohorts had similar fasting serum fatty acid binding protein 4 concentrations at baseline. At 1 year, mean serum fatty acid binding protein 4 decreased by 42% in Roux-en-Y gastric bypass participants (P = .002) but did not change significantly in the intensive lifestyle modification and medical management protocol cohort. Percentage of weight change was not a significant predictor of 12-month fatty acid binding protein 4 within treatment arm or in multivariate models adjusted for treatment arm. In adipose tissue explants, fatty acid binding protein 4 was secreted similarly between visceral and subcutaneous adipose tissue. CONCLUSION: After Roux-en-Y gastric bypass, fatty acid binding protein 4 is reduced 12 months after surgery but not after intensive lifestyle modification and medical management protocol in patients with type 2 diabetes mellitus. Fatty acid binding protein 4 was secreted similarly between subcutaneous and visceral adipose tissue explants. Copyright © 2018 Elsevier Inc. All rights reserved. DOI: 10.1016/j.surg.2018.08.007 PMCID: PMC6389424 PMID: 30287050 [Indexed for MEDLINE] Conflict of interest statement: Disclosure The authors declare no conflict of interest.

Effects of a new combination of  plant extracts plus d-mannose for the management of uncomplicated recurrent urinary tract infections.

10. J Chemother. 2018 Apr;30(2):107-114. doi: 10.1080/1120009X.2017.1393587. Epub 2017 Oct 27. Effects of a new combination of  plant extracts plus d-mannose for the management of uncomplicated recurrent urinary tract infections. Genovese C(1), Davinelli S(2), Mangano K(1), Tempera G(1), Nicolosi D(1), Corsello S(3), Vergalito F(2), Tartaglia E(2), Scapagnini G(2), Di Marco R(2). Author information: (1)a Department of Biomedical and Biotechnological Sciences , University of Catania , Catania , Italy. (2)b Department of Medicine and Health Sciences , University of Molise , Campobasso , Italy. (3)c Obstetrics & Gynecology Division , "Castiglione Prestianni" Hospital , Bronte , Italy. Urinary tract infections (UTIs) are an economic burden for public health. The increasing prevalence of resistant bacteria which cause UTIs may be related to the inappropriate prescription of antibiotics. The aim of this preliminary study was to evaluate whether three different combinations of plant extracts plus d-mannose are effective in preventing the recurrence of UTIs. Three groups of patients received three combinations of plant extracts in conjunction with d-mannose. These were: berberine, arbutin and birch (group A); berberine, arbutin, birch and forskolin (group B); and proanthocyanidins (group C). The clinical recurrence of cystitis at the end of treatment and during follow-up was determined by comparison with baseline measurements using the microbiological assessment of urine samples, vaginal swabs and vaginal smear slides. Patients in groups A and B had a lower incidence of episodes of recurrent cystitis during treatment and follow-up, samples with a significantly lower median bacterial load and a reduction of the grade of lactobacillary flora compared to patients in group C. DOI: 10.1080/1120009X.2017.1393587 PMID: 29078739 [Indexed for MEDLINE]

Cryosurvival and pregnancy rates after exposure of IVF-derived Bos indicus embryos to forskolin before vitrification.

11. Theriogenology. 2013 Sep 1;80(4):372-7. doi: 10.1016/j.theriogenology.2013.04.026. Epub 2013 Jun 6. Cryosurvival and pregnancy rates after exposure of IVF-derived Bos indicus embryos to forskolin before vitrification. Sanches BV(1), Marinho LS, Filho BD, Pontes JH, Basso AC, Meirinhos ML, Silva-Santos KC, Ferreira CR, Seneda MM. Author information: (1)In Vitro Brasil Ltda, Mogi Mirim, São Paulo, SP, Brazil. In vitro-produced (IVP) bovine embryos are more sensitive to cryopreservation than their in vivo counterparts due to their higher lipid concentrations, whereas Bos indicus IVP embryos are even more sensitive than Bos taurus IVP embryos. To examine the effects of a lipolytic agent, before vitrification of Bos indicus IVP embryos, on embryo survival, viability, and pregnancy rates, two experiments were conducted. In experiment 1, Bos indicus (Nelore) embryos were produced from abattoir-derived ovaries and allocated into two groups. In the treatment group, 10 μM of forskolin was added to the in vitro culture medium on Day 5 and incubated for 48 hours. On Day 7 of culture, IVP-expanded blastocysts from both the control (n = 101) and treatment (n = 112) groups were vitrified with ethylene glycol and DMSO via the Cryotop procedure. Although there was no significant difference between the rates of blastocoel reexpansion and hatching of the embryos exposed to forskolin (87.5% and 70.5%, respectively) compared with the control embryos (79.2% and 63.3%, respectively), the numerically superior rates of the embryos exposed to forskolin led to another experiment. In experiment 2, blastocysts produced from the ovum pick up were exposed or not exposed to the lipolytic agent and vitrified as in experiment 1. Embryos treated with forskolin had higher pregnancy rates than the control group (48.8% vs. 18.5%). In view of these results, 1908 Bos indicus embryos were produced from ovum pick up, exposed to the lipolytic agent, and blastocysts were transferred to recipients, and the pregnancy rates of the embryos of various breeds were compared. The mean pregnancy rate obtained was 43.2%. All data were analyzed by chi-square or by binary logistic regression (P ≤ 0.05). In conclusion, treatment with forskolin before vitrification improved cryotolerance of Bos indicus IVP embryos, resulting in good post-transfer pregnancy rates. Copyright © 2013 Elsevier Inc. All rights reserved. DOI: 10.1016/j.theriogenology.2013.04.026 PMID: 23746692 [Indexed for MEDLINE]

Evaluation of the efficacy of a topical cosmetic slimming product combining tetrahydroxypropyl ethylenediamine, caffeine, carnitine, forskolin and retinol, In vitro, ex vivo and in vivo studies.

12. Int J Cosmet Sci. 2011 Dec;33(6):519-26. doi: 10.1111/j.1468-2494.2011.00665.x. Epub 2011 May 13. Evaluation of the efficacy of a topical cosmetic slimming product combining tetrahydroxypropyl ethylenediamine, caffeine, carnitine, forskolin and retinol, In vitro, ex vivo and in vivo studies. Roure R(1), Oddos T, Rossi A, Vial F, Bertin C. Author information: (1)Johnson & Johnson Consumer France, 1 rue Camille Desmoulins, 92787 Issy-Les-Moulineaux, France. rroure@its.jnj.com Three studies were performed to investigate the mechanism of action and evaluate the efficacy of a topical cosmetic slimming product combining tetrahydroxypropyl ethylenediamine, caffeine, carnitine, forskolin and retinol. The Ex vivo study on skin explants showed that caffeine and forskolin both stimulated glycerol release and demonstrates for the first time that retinol and carnitine in combination synergistically stimulated keratinocyte proliferation, which leads to an increase epidermal thickness. The double-blind, randomized, placebo-controlled clinical study associating circumference measurements on five selected parts of the body, cutaneous hydration measurements as well as blinded expert grading of skin aspect was conducted on 78 women who applied the product or placebo twice daily for 12 consecutive weeks. After 4 weeks of twice-daily application of the product, significant reductions in circumference of abdomen, hips-buttocks and waist were already observed. Improvements concerned all the measured body parts after 12 weeks. Orange peel and stubborn cellulite decreased significantly from 4 weeks of treatment and tonicity improved from 8 weeks, demonstrating that the product improved skin aspect. At the end of the study, eight parameters of the thirteen evaluated were significantly improved in the active group and compared with placebo. © 2011 Johnson and Johnson consumer France. ICS © 2011 Society of Cosmetic Scientists and the Société Française de Cosmétologie. DOI: 10.1111/j.1468-2494.2011.00665.x PMID: 21564138 [Indexed for MEDLINE]

Forskolin compared with beclomethasone for prevention of asthma attacks: a single-blind clinical trial.

13. J Int Med Res. 2010 Mar-Apr;38(2):661-8. doi: 10.1177/147323001003800229. Forskolin compared with beclomethasone for prevention of asthma attacks: a single-blind clinical trial. Huerta M(1), Urzúa Z, Trujillo X, González-Sánchez R, Trujillo-Hernández B. Author information: (1)Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Colima, México. This single-blind study compared the efficacy of oral forskolin versus inhaled beclomethasone for mild or moderately persistent adult asthma. Patients were randomly assigned to receive forskolin (one 10-mg capsule orally per day; n = 30) or beclomethasone (two 50 microg inhalations every 12 h; n = 30) for 2 months. No statistically significant improvement occurred in any lung function parameter in the forskolin-treated patients. Subjects in the beclomethasone-treated group presented a slight but statistically significant improvement in percentage forced expiratory volume in 1 s (FEV(1)), percentage forced expiratory flow in the middle (25 - 75%) expiratory phase (FEF(25 - 75%)) and percentage forced vital capacity (FVC) after 2 months of treatment, though the improvement in absolute values for FEV(1), FEF(25 - 75%), FVC and FEV(1):FVC did not reach statistical significance. There was no statistically significant difference between the forskolin and beclomethasone treatment groups for any lung function parameter at baseline or after treatment. None of the beclomethasone-treated patients had an asthma attack and one forskolin-treated patient had a mild asthma attack during the 2-month study period. More studies are needed in adult asthma patients to confirm whether forskolin may be a useful preventive treatment for mild or moderately persistent adult asthma. DOI: 10.1177/147323001003800229 PMID: 20515580 [Indexed for MEDLINE]

Forskolin versus sodium cromoglycate for prevention of asthma attacks: a single-blinded clinical trial.

14. J Int Med Res. 2006 Mar-Apr;34(2):200-7. doi: 10.1177/147323000603400210. Forskolin versus sodium cromoglycate for prevention of asthma attacks: a single-blinded clinical trial. González-Sánchez R(1), Trujillo X, Trujillo-Hernández B, Vásquez C, Huerta M, Elizalde A. Author information: (1)Servicio de Pediatría, Hospital del Instituto Mexicano del Seguro Social, Manzanillo, Colima, México. To determine the efficacy of forskolin in preventing asthma attacks, we performed a single-blinded clinical study in children and adult out-patients at a public hospital in Mexico. Forty patients of either sex with mild persistent or moderate persistent asthma were assigned randomly to 6 months of treatment with forskolin at 10 mg/day orally (capsules) or with two inhalations of sodium cromoglycate every 8 h, i.e. three times a day. The number of patients who had asthma attacks during the treatment period was significantly lower among those receiving forskolin (8/20, 40%) than among those receiving sodium cromoglycate (17/20, 85%). Values of forced expiratory volume in 1 s and forced expiratory flow, mid-phase, A similar in the two groups during the treatment period. We conclude that forskolin is more effective than sod cromoglycate in preventing asthma attacks in patients with mild persistent or moderate persistent asthma. DOI: 10.1177/147323000603400210 PMID: 16749416 [Indexed for MEDLINE]

Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men.

15. Obes Res. 2005 Aug;13(8):1335-43. doi: 10.1038/oby.2005.162. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Godard MP(1), Johnson BA, Richmond SR. Author information: (1)University of Kansas, Department of Health, Sport and Exercise Sciences, Applied Physiology Laboratory, Lawrence, KS 66045, USA. mgodard@ku.edu OBJECTIVE: This study examined the effect of forskolin on body composition, testosterone, metabolic rate, and blood pressure in overweight and obese (BMI > or = 26 kg/m(2)) men. RESEARCH METHODS AND PROCEDURE: Thirty subjects (forskolin, n = 15; placebo, n = 15) were studied in a randomized, double-blind, placebo-controlled study for 12 weeks. RESULTS: Forskolin was shown to elicit favorable changes in body composition by significantly decreasing body fat percentage (BF%) and fat mass (FM) as determined by DXA compared with the placebo group (p < or = 0.05). Additionally, forskolin administration resulted in a change in bone mass for the 12-week trial compared with the placebo group (p < or = 0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with the placebo group (p = 0.097). Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p < or = 0.05). The actual change in serum total testosterone concentration was not significantly different among groups, but it increased 16.77 +/- 33.77% in the forskolin group compared with a decrease of 1.08 +/- 18.35% in the placebo group. DISCUSSION: Oral ingestion of forskolin (250 mg of 10% forskolin extract twice a day) for a 12-week period was shown to favorably alter body composition while concurrently increasing bone mass and serum free testosterone levels in overweight and obese men. The results indicate that forskolin is a possible therapeutic agent for the management and treatment of obesity. DOI: 10.1038/oby.2005.162 PMID: 16129715 [Indexed for MEDLINE]

[Colforsin daropate does not affect the cerebral blood-flow in cardiac surgery patients under cardiopulmonary bypass].

16. Masui. 2004 Apr;53(4):385-90. [Colforsin daropate does not affect the cerebral blood-flow in cardiac surgery patients under cardiopulmonary bypass]. [Article in Japanese] Goto K(1), Mizutani A, Shingu C, Hasegawa A, Hidaka S, Ito K, Iwasaka H, Noguchi T. Author information: (1)Department of Anesthesiology, Oita University School of Medicine, Oita 879-5593. BACKGROUND: Cerebral blood flow partly plays a pivotal role in cerebral complications among cardiac surgery patients. We evaluated the effect of colforsin daropate (colforsin) on cerebral blood flow in cardiac surgery patients under cardiopulmonary bypass (CPB) by transcranial Doppler sonography (TCD). METHODS: Eighteen patients scheduled for coronary artery bypass surgery under CPB were assigned randomly to two groups:colforsin group (n=9) and control group (n=9). We assessed cardiac function by measuring cardiac index (CI) and systemic vascular resistance index (SVRI). Cerebral blood flow was evaluated by measuring the peak systolic blood flow velocity (Vs), end-diastolic blood flow velocity (Vd) together with mean blood flow velocity (Vm), and calculated the pulsatility index (PI) in the left carotid siphon by TCD. After baseline measurement, the colforsin loading dosage was increased from 0.25 to 0.5 microg x kg(-1) x min(-1) in colforsin group every 60 minutes. RESULTS: Colforsin significantly increased CI and decreased SVRI compared with pre-levels. In both groups there were no significant changes in Vs, Vd, Vm and PI. CONCLUSIONS: We have demonstrated that colforsin is effective for hemodynamics without cerebral blood flow change in cardiac surgery patients under cardiopulmonary bypass. PMID: 15160663 [Indexed for MEDLINE]